Daniel is a mechanical and biomedical engineer, former McKinsey & Company management consultant, and deep-tech entrepreneur focused on bringing complex technologies from concept to regulated production. As founder of 3DBio Therapeutics, he led the development of the first 3D-bioprinted living tissue implanted in a human under FDA authorization, a milestone featured on the front page of The New York Times and recognized with Popular Science's Grand Award.

Previously, Daniel was a management consultant at McKinsey & Company, advising Fortune 500 companies across biopharma, industrials, technology, and manufacturing. A three-time Cornell alumnus with undergraduate and doctoral degrees in engineering, he has also held fellowships from the NSF and U.S. Department of Homeland Security.

At ZModal, Daniel brings together deep technical, operational, and industry experience to advance model-driven biomanufacturing from development into production.

David Strachan is a biopharma technology executive and Raman spectroscopy expert with more than 30 years of experience commercializing process analytical technologies across the life sciences. David spent more than two decades leading the commercialization of Raman technology at Kaiser Optical Systems and Endress+Hauser, helping establish Raman as a leading analytical technology for biopharmaceutical manufacturing. His work spanned upstream and downstream bioprocessing, primary pharmaceuticals, and cGxP applications, building relationships across many of the world's largest biopharma companies.

David holds a PhD in Raman spectroscopy from the University of Delaware and a BSc from the University of Strathclyde. Throughout his career, he has worked at the intersection of spectroscopy, process automation, and pharmaceutical manufacturing, from pioneering early process NIR applications to advancing enterprise-scale Raman and PAT deployments.

As Chief Commercial Officer at ZModal, David brings deep technical expertise, industry relationships, and decades of commercialization experience to accelerate the adoption of model-driven biomanufacturing.

James is Head of Engineering at ZModal, with extensive experience developing automation, robotics, embedded systems, and software for complex, regulated technologies.

Before joining ZModal, James was Staff Engineer at 3DBio Therapeutics, where he led development of the software and firmware underpinning the company’s clinical 3D bioprinting platform. He also led GMP validation of the bioprinter, including computer system validation and implementation of controls supporting 21 CFR Part 11 compliance. That platform supported 3DBio Therapeutics' successful FDA acceptance of its Investigational New Drug (IND) application and was used to manufacture the first 3D-bioprinted living tissue ever implanted in humans.

James brings deep experience across industrial automation, robotics, embedded firmware, real-time control systems, regulated software, and the translation of advanced engineering systems from development into validated production environments.